$0.03
+0.00%Oct 13, 2026, 11:00 UTC
Veraxa Biotech Holding AG presented first in vivo proof-of-concept data for its BiTAC®-ADC technology at the World ADC Congress, showing tumor-selective activation, potent anti-tumor efficacy and improved safety.
Source:Sep 24, 2026, 15:59 UTC
VERAXA Biotech is shifting focus to advancing its oncology pipeline and implementing industrial partnerships for its technology platforms and products after completing its business combination and starting Nasdaq trading in June 2026.
Source:Jul 13, 2026, 11:00 UTC
VERAXA Biotech announced a collaboration with Ardigen to support its BiTAC pipeline of T cell engagers and antibody drug conjugates.
Source:Jun 15, 2026, 00:00 UTC
Xlife Sciences AG disclosed a 16.3% stake in Veraxa Biotech Holding AG via a 13D/G filing.
Jun 10, 2026, 20:15 UTC
VERAXA Biotech completed a business combination with Voyager Acquisition Corp. and will begin trading on NASDAQ under ticker VRXA on June 11, 2026.
Source:May 29, 2026, 00:00 UTC
Voyager Acquisition Corp. issued $27.5 million aggregate principal amount of Senior Secured Notes due August 27, 2027, with monthly partial redemption payments of $2.75 million, secured by a first-priority lien on assets, for working capital and general corporate purposes.